Cue Biopharma, Inc.
Cue Biopharma develops therapies for immunological disorders using its Immuno-STAT platform to target disease-specific T cells.
10-QNov 16Latest SEC filing
Nov 16Latest story
November 2026
September 2026
August 2026
July 2026
Cue Biopharma develops therapies for immunological disorders using its Immuno-STAT platform to target disease-specific T cells.
November 2026
September 2026
August 2026
July 2026